On March 23, 2026, global healthcare company Viatris Inc. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Effexor SR capsules (venlafaxine hydrochloride) for the treatment of adults with generalized anxiety disorder (GAD). Following this decision, Effexor becomes the first and only approved treatment option for GAD in Japan.
Key details regarding the approval:
-
Mechanism of Action: Effexor is a serotonin-noradrenaline reuptake inhibitor (SNRI). It was previously approved in Japan specifically for the indication of major depressive disorder in adults.
-
Scientific Basis: The approval is supported by a Phase 3 randomized, double-blind, multicenter study conducted in Japan. The trial met its primary endpoint, demonstrating the clinical superiority of venlafaxine’s anxiolytic effects compared to a placebo over an 8-week period, as measured by the Hamilton Anxiety Rating Scale (HAM-A).
-
Safety and Tolerability: The drug was generally well-tolerated, showing a safety profile consistent with its established record in non-Japanese patient populations.
-
Global Footprint: Effexor is currently authorized to treat GAD in more than 80 countries worldwide.
The expansion of this indication provides a formal medical pathway for patients suffering from persistent anxiety in Japan, where specific pharmacological options for GAD were previously unavailable.